Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOMG Phase 1 Study of Lomustine Alone and With Procarbazine + Vincristine in Japanese Patients With Glioma
jRCT2051230069Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lomustine in glioma, Oligodendroglioma (OG) and astrocytoma (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity (DLT) in Cycle 1 - lomustine monotherapy and Dose-limiting toxicity (DLT) in Cycle 1 - PCV combination. Started Aug 2023; status: recruiting.
02
Drugs
lomustine
03
Conditions
gliomaOligodendroglioma (OG)astrocytoma
Beyond the preview
Go deeper on jRCT2051230069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230069.